诱导多能干细胞来源的CD19靶向嵌合抗原受体自然杀伤细胞治疗B细胞淋巴瘤:1期首次人体试验
这项1期首次人体试验在美国9个中心评估了诱导多能干细胞来源的CD19靶向嵌合抗原受体自然杀伤细胞FT596单药或联合利妥昔单抗治疗复发或难治性B细胞淋巴瘤的安全性和推荐2期剂量。86例患者接受治疗,未达到最大耐受剂量,细胞因子释放综合征发生率低,神经毒性未观察到,FT596耐受良好并诱导了深度持久缓解,推荐2期剂量初步确定为每周期3剂共1.8×10^9个细胞。
要点
- FT596单药或联合利妥昔单抗耐受良好,未达到最大耐受剂量。
- 细胞因子释放综合征发生率低,A方案1例(6%),B方案9例(13%),神经毒性未观察到。
- 推荐2期剂量初步确定为每周期3剂共1.8×10^9个细胞。
核心结论
- FT596单药或联合利妥昔单抗耐受良好,在惰性和侵袭性淋巴瘤患者中诱导了深度持久缓解,推荐2期剂量初步确定为每周期3剂共1.8×10^9个细胞。
- 本研究支持使用诱导多能干细胞来源的基因修饰自然杀伤细胞的细胞疗法是癌症治疗的有力平台,并提示该平台可能解决现有免疫细胞疗法在制造时间、异质性、可及性和成本方面的局限性。
研究设计与样本
- 1期首次人体试验,在美国9个中心纳入复发或难治性B细胞淋巴瘤患者,接受过至少一种既往全身治疗且无治愈性治疗选择。
- FT596在预处理化疗后给药,不联合利妥昔单抗(A方案)或联合利妥昔单抗(B方案)。
- 剂量递增阶段采用3+3设计,从第1天单次给予3×10^7个活细胞开始,各方案独立递增。
- 一个治疗周期包括第-5天至第-3天静脉给予环磷酰胺(500 mg/m2)和氟达拉滨(30 mg/m2)预处理化疗,随后给予不同剂量和方案的FT596,A方案不联合利妥昔单抗,B方案联合第-4天静脉单次利妥昔单抗(375 mg/m2)。
- 剂量扩展阶段在已确定可耐受的选定剂量和给药方案下评估更多患者。
主要发现
- 2020年3月19日至2023年1月12日,86例B细胞淋巴瘤患者接受FT596,A方案18例,B方案68例。
- 86例患者中22例(26%)为女性,72例(84%)为白人;既往治疗中位线数为4线(范围1-11),33例(38%)既往接受过CAR T细胞治疗。
- 未达到最大耐受剂量。
- 细胞因子释放综合征在A方案18例中报告1例(6%,最高1级),在B方案68例中报告9例(13%,其中6例最高1级,3例2级)。
- 未观察到神经毒性。
关键数值与推荐
- 主要终点为各剂量递增队列中剂量限制性毒性的发生率和性质,以确定最大耐受剂量或最大评估剂量并建立推荐2期剂量,以及不良事件的发生率、性质和严重程度(严重程度按美国国家癌症研究所常见毒性标准及不良事件版本5.0确定)。
- 剂量限制性不良事件观察期为28天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FT596 is an induced pluripotent stem-cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy with three antitumour modalities: a CD19 CAR; a high-affinity, non-cleavable CD16 Fc receptor; and interleukin-15-interleukin-15 receptor fusion. In this study, we aimed to determine the recommended phase 2 dose (RP2D) and evaluate the safety and tolerability of FT596 as monotherapy and in combination with rituximab. We also aimed to evaluate the antitumour activity and characterise the pharmacokinetics of FT596 as monotherapy and in combination with rituximab. METHODS: In this phase 1, first-in-human trial, we evaluated FT596 in patients with relapsed or refractory B-cell lymphoma at nine sites in the USA. Patients who had received at least one previous systemic therapy and had no curative treatment options were eligible for inclusion. FT596 was administered after conditioning chemotherapy without rituximab (regimen A) or combined with rituximab (regimen B). The study consisted of a dose-escalation phase using a 3 + 3 design, with dose escalation commencing at 3 × 107 viable cells as a single dose on day 1 and done independently for individual regimens. A treatment cycle consisted of conditioning chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) intravenously on days -5 to -3, followed by FT596 administered at various doses and schedules, without (regimen A) or with (regimen B) a single dose of rituximab (375 mg/m2) intravenously on day -4. Supportive care was determined by the treating investigator. Patients were observed for dose-limiting adverse events for 28 days. Patients who tolerated therapy and derived clinical benefit could receive subsequent cycles of study treatment, with modification of conditioning chemotherapy dose if clinically indicated. The dose-expansion phase evaluated additional patients at selected doses and dosing schedules that had been found to be tolerable. The primary endpoints of the study were the incidence and nature of dose-limiting toxicities within each dose-escalation cohort to determine the maximum tolerated dose or maximum assessed dose to establish the RP2D and the incidence, nature, and severity of adverse events, with severity determined according to National Cancer Institute Common Toxicity Criteria and Adverse Events version 5·0. The trial was registered with ClinicalTrials.gov, NCT04245722. FINDINGS: Between March 19, 2020, and Jan 12, 2023, 86 patients with B-cell lymphoma received FT596 on regimen A (n=18) or regimen B (n=68). 22 (26%) of 86 patients were female and 72 (84%) of 86 patients were White. Patients had received a median of four previous lines of therapy (range 1-11) and 33 (38%) of 86 patients had received previous CAR T-cell therapy. The maximum tolerated dose was not reached. Cytokine release syndrome was reported in one (6%) of 18 patients (maximum grade 1) on regimen A and nine (13%) of 68 patients on regimen B (six with maximum grade 1 and three with grade 2). Neurotoxicity was not observed. INTERPRETATION: FT596 was well tolerated as monotherapy or with rituximab and induced deep and durable responses in patients with indolent and aggressive lymphomas and the RP2D was preliminarily identified to be 1·8 × 109 cells for three doses per cycle. This study supports that cell therapy using iPSC-derived, gene-modified NK cells is a potent platform for cancer treatment and suggests that such a platform might address limitations of currently available immune cell therapies, including manufacturing time, heterogeneity, access, and cost. FUNDING: Fate Therapeutics.
引用
- Ghobadi A, Bachanova V, Patel K, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025. PMID: 39798981. doi:10.1016/S0140-6736(24)02462-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。